FLT3 (FMS-like Tyrosine Kinase 3) is a class III receptor tyrosine kinase expressed primarily in hematopoietic progenitor cells. While best characterized in acute myeloid leukemia (AML), FLT3 is also expressed in the central nervous system, where it plays important roles in neuronal development, survival, and immune function. Emerging research suggests FLT3 signaling may be relevant to neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), through effects on [microglia](/cell-types/microglia-neuroinflammation) and neuroinflammation [1].
FLT3 (FMS-like Tyrosine Kinase 3) is a class III receptor tyrosine kinase expressed primarily in hematopoietic progenitor cells. While best characterized in acute myeloid leukemia (AML), FLT3 is also expressed in the central nervous system, where it plays important roles in neuronal development, survival, and immune function. Emerging research suggests FLT3 signaling may be relevant to neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), through effects on [microglia](/cell-types/microglia-neuroinflammation) and neuroinflammation [1].
Structure and Signaling
Receptor Architecture
FLT3 is a type I transmembrane receptor consisting of:
Extracellular domain: 5 immunoglobulin-like domains for ligand binding
Transmembrane helix: Single pass through the membrane
[Alpha-synuclein](/proteins/alpha-synuclein) pathology: Interaction with microglial responses
Therapeutic targeting: FLT3 inhibitors in development
Neuroinflammation
FLT3 as a therapeutic target for neuroinflammation:
FLT3 inhibitors reduce microglial activation
Potential for disease modification
Selective targeting in the CNS
FLT3 in Neurodevelopment
Neuronal Development
During brain development, FLT3:
Promotes neuronal progenitor proliferation
Supports differentiation
Regulates migration
Influences synapse formation
Therapeutic Potential
Understanding FLT3 in development suggests:
Developmental disorder treatments
Regenerative medicine approaches
Stem cell therapy enhancement
Clinical Implications
FLT3 Inhibitors
FDA-approved FLT3 inhibitors (primarily for AML) include:
Midostaurin
Gilteritinib
Quizartinib
Potential CNS applications:
Reduce neuroinflammation
Modulate microglial function
Combined with other therapies
Biomarker Potential
FLT3 expression may serve as:
Marker of microglial activation
Biomarker for disease progression
Therapeutic response indicator
Summary
FLT3 is a receptor tyrosine kinase expressed in microglia and neurons in the central nervous system. While extensively studied in hematological malignancies, FLT3 signaling in the brain influences neuroinflammation, microglial function, and neuronal survival. Dysregulated FLT3 activity contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders through effects on inflammatory processes. FLT3 represents a potential therapeutic target for modulating neuroinflammation in these conditions.